Exclusive: Vertex founder Joshua Boger joins tiny Boston biotech as chair, ahead of mid-stage readout for dementia drug
Since ending a two-decade tenure as Vertex Pharmaceuticals’ CEO in 2009, Joshua Boger has had no lack of opportunities to jump on biotech boards.
He’s said no to virtually every offer — except this one. Boger exclusively told Endpoints News he will join CervoMed as its chair. It’s the second biotech board seat Boger has taken on after Vertex, alongside his executive chair role at Alkeus Pharmaceuticals, which is developing a drug for Stargardt disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.